@entity157 ( @entity157 ) accounts for most primary @entity409 . The most important risk factor is @entity1575 . @entity157 can be traced by the @entity5 marker @entity160 . @entity1 with a known @entity1575 should regularly be screened, including sonography and @entity160 evaluation. Surgical therapy - either partial liver resection or liver transplantation - is the only treatment that can potentially achieve long-term survival. The presence of @entity1575 is likely to induce @entity7752 and is associated with higher local @entity5 recurrence rate. @entity1 without @entity1575 or @entity1 -Pugh A @entity1 with @entity5 smaller than 5 cm may be considered as the ideal target group for resection. For more advanced stages of @entity82 and @entity5 of less than 5 cm up to 7 cm in size, liver transplantation offers a better prognosis. Long waiting time for a suitable organ negatively influences liver transplantation outcome. Living donor liver transplantation is a novel therapeutic option that improves posttransplant survival and extends the indication for transplantation in @entity157 .

[Surgical therapy of XXXX ].

@entity1 :: ('9606', 'Species') :: ['Child', 'Patients', 'patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity409 :: ('MESH:D008107', 'Disease') :: ['malignancies of the liver'] @entity7752 :: ('MESH:D048550', 'Disease') :: ['postoperative liver insufficiency'] @entity160 :: ('174', 'Gene') :: ['alpha-fetoprotein'] @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Hepatocellular carcinoma', 'hepatocellular carcinoma']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
